Arbutus beats Q2 revenue, net income expectations

Arbutus Biopharma

06/08/2025 12:44

Overview

Arbutus Q2 revenue of $10.7 mln beats analyst expectations, per LSEG data

Net income for Q2 beats estimates, contrasting with a loss last year

Company reacquired Greater China rights to imdusiran, boosting revenue

Outlook

Company holds global rights for imdusiran after ending Qilu partnership

Arbutus focuses on cHBV programs following strategic partnership changes

Ongoing litigation against Moderna and Pfizer/BioNTech may impact future results

Result Drivers

REVENUE BOOST - Reacquisition of Greater China rights to imdusiran led to recognition of previously-deferred revenue

COST REDUCTION - Streamlining efforts and workforce reduction decreased research and development expenses

EXPENSE MANAGEMENT - Lower general and administrative expenses due to cost-cutting measures

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$10.70 mln
$1.59 mln (4 Analysts)
Q2 Net Income
Beat
$2.50 mln
-$8.67 mln (2 Analysts)
Q2 Cash & Investments
$98.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00, about 31.8% above its August 5 closing price of $3.41

Press Release: ID:nGNX5F0LW7

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)